Xytram-S Tablet is a combination analgesic formulation containing Tramadol hydrochloride (37.5 mg), Paracetamol (325 mg), and Serratiopeptidase (15 mg), designed for the effective management of moderate to severe pain accompanied by inflammation. Tramadol, a centrally acting opioid analgesic, exerts its effect by binding to the mu-opioid receptors and inhibiting the reuptake of norepinephrine and serotonin, thereby modulating pain perception. Paracetamol, a non-opioid analgesic and antipyretic agent, provides additional pain relief and fever reduction through central inhibition of prostaglandin synthesis. Serratiopeptidase, a proteolytic enzyme, facilitates the reduction of inflammation and edema by breaking down inflammatory mediators and promoting the drainage of inflammatory exudates. The synergistic action of these three components makes Xytram-S effective in managing postoperative pain, musculoskeletal disorders, dental pain, and other conditions characterized by pain and inflammation. It is recommended to be used under medical supervision, considering potential contraindications such as hypersensitivity to any component, history of seizures, or severe hepatic or renal impairment. Caution is advised when administered concomitantly with other central nervous system depressants or serotonergic drugs to avoid adverse effects. Xytram-S should be taken as prescribed to ensure optimal therapeutic outcomes and minimize the risk of side effects.